Company: INTS
Filing Date: 2025-06-12
Form Type: 424B5
Source: 0001628280-25-031040
Chunk: 43

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-06-12
Form: 424B5
Chunk 43
---
01 of Form 8-K and exhibits filed on such form that are related to such items and other portions of documents that are furnished, but not filed, pursuant to applicable rules promulgated by the SEC) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the filing and concurrent effectiveness of the registration statement but prior to the termination of all offerings covered by this prospectus supplement:

• Our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 13, 2025 ;

• Our Quarterly Report on From 10-Q for the period ending March 31, 2025, filed with the SEC on May 13, 2025 ;

• Our current reports on Form 8-K filed with the SEC on April 25, 2025 , May 20, 2025 and June 6, 2025 ; and

• The description of the Common Stock set forth in our registration statement on Form 8-A, filed with the SEC on November 30, 2021 , as amended on December 2, 2021 , including any amendment or report filed for the purpose of updating such description.

Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for all purposes to the extent that a statement contained in this prospectus supplement and the accompanying prospectus or in any other subsequently filed document which is also incorporated or deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement or the accompanying prospectus. You may request a copy of these filings (other than an exhibit to a filing unless that exhibit is specifically incorporated by reference into that filing) at no cost by writing, telephoning or e-mailing us at the following address or telephone number:

<div align='center'>Intensity Therapeutics, Inc.

1 Enterprise Drive, Suite 430

Shelton, CT 06484

(203) 221-7381

Attention: Joseph Talamo, Chief Financial Officer</div>

You may also access these documents, free of charge on the SEC’s website at www.sec.gov or on our website at www.intensitytherapeutics.com. Information contained on our website is not incorporated by reference into this prospectus supplement or the